This analysis describes what Writer's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
The updated terms establish clearer scope (these terms apply to free, trial, and paid versions; Enterprise is separate) and expand the list of prohibited uses. Users may no longer reverse engineer, scrape, or attempt to derive components of the Services; use the platform for competitive analysis or to develop competing products; or misrepresent AI-generated output as human-created. The terms also explicitly prohibit processing of HIPAA-regulated health information. Users can review the full updated terms to understand which specific uses are now restricted.
View change record →How other platforms handle this
These Terms and Conditions are personal to you, and are not assignable, transferable, or sublicensable by you except with Teladoc Health's prior written consent.
We may assign our rights or obligations under these Terms to any affiliate, subsidiary, or successor in interest of any business associated with our Services.
You may not assign your rights under the Agreement, by operation of law or otherwise, without our consent.
"We reserve the right to assign the Terms or any rights contained herein to any affiliate or successor in interest in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of our assets.Excerpt from Writer's Terms of Service
Get the weekly coverage letter
Companies change their terms without announcing it. We capture governance documents, compare each new version with the last, and publish what changed, with the source text behind it. One email a week on what we found and what we could not reach.
The clause states: “We reserve the right to assign the Terms or any rights contained herein to any affiliate or successor in interest in connection with a merger, acquisition, corporate reorganization, or sale of all or substantially all of our assets.”
ConductAtlas has identified this type of provision across 290 platforms. See the full comparison.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by Writer.